全文获取类型
收费全文 | 157篇 |
免费 | 21篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 12篇 |
基础医学 | 13篇 |
临床医学 | 9篇 |
内科学 | 67篇 |
皮肤病学 | 1篇 |
神经病学 | 7篇 |
外科学 | 33篇 |
综合类 | 2篇 |
预防医学 | 1篇 |
药学 | 13篇 |
肿瘤学 | 22篇 |
出版年
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 8篇 |
2017年 | 11篇 |
2016年 | 5篇 |
2015年 | 6篇 |
2014年 | 9篇 |
2013年 | 36篇 |
2012年 | 7篇 |
2011年 | 9篇 |
2010年 | 4篇 |
2009年 | 14篇 |
2008年 | 19篇 |
2007年 | 9篇 |
2006年 | 14篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 2篇 |
2002年 | 3篇 |
排序方式: 共有180条查询结果,搜索用时 31 毫秒
1.
2.
《Expert review of anticancer therapy》2013,13(9):1379-1390
Chronic lymphocytic leukemia (CLL) exhibits a highly variable natural history, but the addition of genomic risk stratification to traditional clinical staging systems has begun to explain the heterogeneous clinical course. Overall response to treatment has significantly improved over the past three decades and for the first time, a survival benefit has been demonstrated with the use of monoclonal antibodies in combination with cytotoxic chemotherapy. Newer therapeutic strategies have abrogated the adverse prognosis associated with some higher risk features, but other genetic subgroups remain at high risk for rapid disease progression and early mortality. Patients at advanced age or with significant comorbidity constitute a large proportion of the CLL population and present unique clinical challenges. This article will discuss the evolution of contemporary therapeutic approaches to the initial treatment of CLL, and highlight the ways in which risk-adapted therapeutic strategies are improving clinical outcomes. 相似文献
3.
Marie Robin Kavita Raj Sylvie Chevret Jordan Gauthier Hugues de Lavallade David Michonneau Donal McLornan Régis Peffault de Latour Victoria Potter Austin Kulasekararaj Flore Sicre de Fontbrune Antonio Pagliuca Ibrahim Yakoub‐Agha Gérard Socié Ghulam J. Mufti 《European journal of haematology》2018,101(4):466-474
4.
5.
6.
7.
8.
Antonio Maria Risitano Carmine Selleri Bianca Serio Giovanni Fernando Torelli Alexander Kulagin Sébastien Maury Jörg Halter Vikas Gupta Andrea Bacigalupo Gerard Sociè André Tichelli Hubert Schrezenmeier Judith Marsh Jakob Passweg Bruno Rotoli 《British journal of haematology》2010,148(5):791-796
An alemtuzumab‐based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73–103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune‐mediated marrow failures. 相似文献
9.
《Expert opinion on pharmacotherapy》2013,14(7):1535-1554
Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a ‘cure’. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL. 相似文献
10.
Ferrajoli A Wierda WG LaPushin R O'Brien SM Faderl S Browning ML Keating MJ 《European journal of haematology》2008,80(4):296-298
We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population. 相似文献